Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

Disordini dello “spettro Zellweger”:
rara causa di convulsioni e ipotonia nel neonato

“Zellweger spectrum” disorders: rare cause of seizures and hypotonia in the newborn

Gabriela Stangoni, Tiziana Becchetti, Giulia Maria Campus, Ambra Fantauzzi, Raffaella Scattoni, Aurelija Zeringyte
Unità di Patologia e Terapia Intensiva Neonatale, Ospedale Santa Maria della Misericordia, Perugia

Novembre 2016

Abstract

The paper describes a case of a newborn suffering from severe hypotonia and drug-resistant seizures, who was diagnosed with a "Zellweger spectrum" disease by means of biochemical and enzymatic tests. The "Zellweger spectrum" disorders are a group of diseases including Zellweger syndrome, neonatal adrenoleukodystrophy and Refsum disease which are considered as a "clinical and biochemical continuum", characterized by the loss of peroxisomal functions, caused by molecular defects in genes coding for peroxins, proteins required for peroxisome biogenesis.

Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta 2012;1822:1430-41.
  2. Lee PR, Raymond GV. Child neurology: Zellweger syndrome. Neurology 2013;80:207-10.
  3. Aubourg P, Wanders R. Peroxisomal disorders. Handb Clin Neurol 2013;113:1593-609.
  4. Krause C, Rosewich H, Thanos M, Gärtner J. Identification of novel mutations in PEX2, PEX6, PEX10, PEX12, and PEX13 in Zellweger spectrum patients. Hum Mutat 2006;27:1157.
  5. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochim Biophys Acta 2006;1763:1733-48.
  6. FitzPatrick DR. Zellweger syndrome and associated phenotypes. J Med Genet 1996;33:863-8.
  7. Çim A, Coşkun S, Görükmez O, et al. Rhizomelic Chondrodysplasia Punctata Type 1 Caused by a Novel Mutation in the PEX7 Gene. J Clin Res Pediatr Endocrinol 2015;7:69-72.
  8. Nascimento J, Mota C2, Lacerda L, et al. D-bifunctional protein deficiency: a cause of neonatal onset seizures and hypotonia. Pediatr Neurol 2015;52:539-43.
  9. Salpietro V, Phadke R, Saggar A, et al. Zellweger syndrome and secondary mitochondrial myopathy. Eur J Pediatr 2015;174(4):557-63.
  10. Braverman NE, D’Agostino MD, Maclean GE. Peroxisome biogenesis Disorders: Biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev 2013;17:187-96.
  11. Krause C, Rosewich H, Gärtner J. Rational diagnostic strategy for Zellweger syndrome spectrum patients. Eur J Hum Genet 2009;17:741-8.
  12. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001;16:309-16.
  13. Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: result on double-blind, randomized trial. Neurology 2010;75:826-30.
  14. Wei H, Kemp S, McGuinness MC, Moser AB, Smith KD. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol 2000;47:286-96.